A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...